Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Subunit B/Bacterial Cholera Vaccine Against Infectious Diarrhea in Healthy People Aged 2 to 14 Years
NCT07300462Phase 4Enrolling by invitation
- Sponsor
- Shanghai United Cell Biotechnology Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gastroenteritis comparing Recombinant subunit B/bacterial cholera vaccine with Placebo (2 arms). Primary endpoint: Incidence of infectious diarrhea at 180 days. Started Apr 2026; status: enrolling by invitation.
02
Drugs
recombinant B subunit/whole-cell cholera vaccine
03
Conditions
gastroenteritis
Beyond the preview
Go deeper on NCT07300462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300462.